Is Scemblix used for CML?

Is Scemblix (asciminib) actually used for chronic myeloid leukemia (CML)?

Yes. Scemblix (asciminib) is a treatment for chronic myeloid leukemia (CML), specifically for patients with CML who have the Philadelphia chromosome (Ph+) and are treated in the chronic phase after prior therapy. It targets the BCR-ABL1 pathway through a different mechanism than standard tyrosine kinase inhibitors (TKIs). [1]

When in CML treatment is Scemblix used?

Scemblix is used for CML in situations where patients need therapy after earlier treatments, rather than as a first-line option for most patients. [1]

How does Scemblix differ from typical CML TKIs?

Standard CML TKIs inhibit BCR-ABL1 kinase activity. Scemblix (asciminib) works differently by inhibiting BCR-ABL1 with a distinct binding approach, aiming at the same leukemia-driving target but via another mode of action. [1]

Where can I check the latest labeled uses and restrictions?

For up-to-date information on drug labeling, approvals, and patent/exclusivity context, DrugPatentWatch.com is a useful reference point. [1]

Sources
[1] https://www.drugpatentwatch.com/